# US 7,608,688 B2 · HIV-1 protein associated with broadly reactive neutralizing antibody response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,688 B2
- Document ID: US7608688B2
- Status: Granted
- Kind: B2
- Application number: 11/473,036
- Filed: 2006-06-23
- Published: 2007-01-11
- Granted: 2009-10-27
- Earliest claimed: 1998-08-04
- Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Inventors: Gerald V. Quinnan, Jr.; Peng Fei Zhang
- Web page: https://patentgrep.com/patent/US7608688B2

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61P 31/18: for HIV
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y10S 530/826: Viruses
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins.

## Claims

### Claim 1

An isolated nucleic acid molecule encoding an HIV-1 envelope protein comprising SEQ ID NO: 1.

### Claim 2

An isolated nucleic acid molecule encoding an HIV-1 envelope protein capable of inducing the production of a cross-reactive neutralizing anti-serum against multiple strains of HIV-1 in vitro comprising the amino acid sequence of SEQ ID NO:1.

### Claim 3

An isolated nucleic acid molecule encoding an HIV-1 envelope protein capable of inducing the production of a cross-reactive neutralizing anti-serum against multiple strains of HIV-1 in vitro wherein the V3 region of the HIV-1 envelope protein comprises SEQ ID NO:3.

### Claim 4

An isolated nucleic acid molecule which encodes an HIV-1 envelope protein having a V3 region comprising SEQ ID NO:3.

### Claim 5 (depends on 2)

The isolated nucleic acid molecule of claim 2, wherein the nucleic acid molecule encodes an HIV-1 envelope protein consisting of SEQ ID NO:1.

### Claim 6 (depends on 2)

The isolated nucleic acid molecule of claim 2, wherein said nucleic acid molecule is operably linked to one or more expression control elements.

### Claim 7 (depends on 6)

A recombinant vector comprising the nucleic acid molecule of claim 6.

### Claim 8 (depends on 7)

The recombinant vector of claim 7, wherein the recombinant vector is a plasmid.

### Claim 9 (depends on 8)

The plasmid of claim 8, wherein the plasmid is psV7d env, which has been deposited with ATCC under accession number PTA-7237.

### Claim 10 (depends on 7)

The recombinant vector of claim 7, wherein the recombinant vector is an attenuated virus.

### Claim 11 (depends on 10)

A composition comprising a recombinant vector of claim 10 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 10)

An isolated host cell line comprising the vector of claim 10.

### Claim 13 (depends on 12)

The host cell line of claim 12, wherein the host cell is stably transformed with the vector.

### Claim 14 (depends on 12)

The host cell line of claim 12, wherein said host is a prokaryotic host cell.

### Claim 15 (depends on 12)

The host cell line of claim 12, wherein said host cell is a eukaryotic host cell.

### Claim 16 (depends on 3)

The isolated nucleic acid molecule of claim 3, wherein the HIV-1 envelope protein molecule comprises 50 amino acid residues.

### Claim 17 (depends on 3)

The isolated nucleic acid molecule of claim 3, wherein the HIV-1 envelope protein further comprises a C3 region.

### Claim 18 (depends on 4)

The isolated nucleic acid molecule of claim 4, wherein the HIV-1 envelope protein further comprises a C3 region.

### Claim 19 (depends on 3)

The isolated nucleic acid molecule of claim 3, wherein said nucleic acid molecule is operably linked to one or more expression control elements.

### Claim 20 (depends on 19)

A recombinant vector comprising a nucleic acid molecule of claim 19.

### Claim 21 (depends on 20)

The recombinant vector of claim 20, wherein the recombinant vector is a plasmid.

### Claim 22 (depends on 20)

The recombinant vector of claim 20, wherein the recombinant vector is an attenuated virus.

### Claim 23 (depends on 20)

A composition comprising a recombinant vector of claim 20 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 20)

An isolated host cell line comprising the vector of claim 20.

### Claim 25 (depends on 24)

The host cell line of claim 24, wherein the host cell is stably transformed with the vector.

### Claim 26 (depends on 24)

The host cell line of claim 24, wherein said host is a prokaryotic host cell.

### Claim 27 (depends on 24)

The host cell line of claim 24, wherein said host cell is a eukaryotic host cell.